argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
644.48
-3.01 (-0.46%)
Feb 21, 2025, 4:00 PM EST - Market closed
argenx SE Revenue
argenx SE had revenue of $588.88M in the quarter ending September 30, 2024, with 73.28% growth. This brings the company's revenue in the last twelve months to $1.91B, up 85.56% year-over-year. In the year 2023, argenx SE had annual revenue of $1.27B with 187.66% growth.
Revenue (ttm)
$1.91B
Revenue Growth
+85.56%
P/S Ratio
20.60
Revenue / Employee
$1,662,595
Employees
1,148
Market Cap
39.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.27B | 827.59M | 187.66% |
Dec 31, 2022 | 441.01M | -87.26M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | 92.81M | 63.58M | 217.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARGX News
- 2 days ago - argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - GlobeNewsWire
- 5 weeks ago - argenx Highlights 2025 Strategic Priorities - GlobeNewsWire
- 6 weeks ago - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 3 months ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewsWire
- 3 months ago - Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics - Business Wire
- 3 months ago - argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China - GlobeNewsWire